Q-omics provides the consensus-scored RASL12 profile across patient tissues and cancer cell-line models. RASL12 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RASL12 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, RASL12 protein abundance shows 38,850 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, BLCA, and LSCC as cancer lineages where RASL12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RASL12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RASL12 survival associations across molecular data types. RASL12 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RASL12 RNA expression–survival associations across cancer types. High RASL12 expression shows unfavorable associations in UVM, BLCA, LUSC and MESO, but favorable associations in HNSC and CHOL. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for RASL12 RNA expression.
This table summarizes RASL12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 11. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RASL12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RASL12 shows lower tumor expression in BLCA, KICH, LUSC and LUAD and higher tumor expression in KIRC and LIHC. The BLCA box plot shows higher RASL12 RNA expression in normal versus tumor tissue (log2 FC = −4.240, t-test p < 0.001).
This table shows molecular features associated with RASL12 in patient tissues and cancer cell lines. In patient samples, RASL12 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RASL12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BONE and OVARY.
